1. Home
  2. ELVN vs THRM Comparison

ELVN vs THRM Comparison

Compare ELVN & THRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • THRM
  • Stock Information
  • Founded
  • ELVN 2016
  • THRM 1991
  • Country
  • ELVN United States
  • THRM United States
  • Employees
  • ELVN N/A
  • THRM N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • THRM Auto Parts:O.E.M.
  • Sector
  • ELVN Health Care
  • THRM Consumer Discretionary
  • Exchange
  • ELVN Nasdaq
  • THRM Nasdaq
  • Market Cap
  • ELVN 1.1B
  • THRM 1.0B
  • IPO Year
  • ELVN 2020
  • THRM 1993
  • Fundamental
  • Price
  • ELVN $21.00
  • THRM $32.66
  • Analyst Decision
  • ELVN Strong Buy
  • THRM Buy
  • Analyst Count
  • ELVN 5
  • THRM 3
  • Target Price
  • ELVN $37.80
  • THRM $51.67
  • AVG Volume (30 Days)
  • ELVN 213.5K
  • THRM 308.4K
  • Earning Date
  • ELVN 03-17-2025
  • THRM 04-29-2025
  • Dividend Yield
  • ELVN N/A
  • THRM N/A
  • EPS Growth
  • ELVN N/A
  • THRM 68.85
  • EPS
  • ELVN N/A
  • THRM 2.06
  • Revenue
  • ELVN N/A
  • THRM $1,456,124,000.00
  • Revenue This Year
  • ELVN N/A
  • THRM $1.98
  • Revenue Next Year
  • ELVN N/A
  • THRM $4.98
  • P/E Ratio
  • ELVN N/A
  • THRM $15.85
  • Revenue Growth
  • ELVN N/A
  • THRM N/A
  • 52 Week Low
  • ELVN $10.90
  • THRM $30.25
  • 52 Week High
  • ELVN $30.03
  • THRM $57.96
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 47.82
  • THRM 37.70
  • Support Level
  • ELVN $18.67
  • THRM $30.66
  • Resistance Level
  • ELVN $22.36
  • THRM $34.15
  • Average True Range (ATR)
  • ELVN 1.07
  • THRM 1.52
  • MACD
  • ELVN 0.06
  • THRM -0.01
  • Stochastic Oscillator
  • ELVN 60.84
  • THRM 40.44

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

About THRM Gentherm Inc

Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.

Share on Social Networks: